|
2023
|
Invention
|
Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors.
The inv... |
|
|
Invention
|
Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors.
The disclosure ... |
|
|
Invention
|
Inhibiting cyclic amp-responsive element-binding protein (creb) binding protein (cbp).
The prese... |
|
|
Invention
|
Bromodomain inhibitors for androgen receptor-driven cancers.
Methods for treating certain androg... |
|
|
Invention
|
Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors.
The present disclosure is dire... |
|
|
Invention
|
Inhibiting mutant isocitrate dehydrogenase 1 (midh-1).
Patients diagnosed with a cancer harborin... |
|
|
Invention
|
Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,... |
|
|
Invention
|
Usp1 inhibitors and uses thereof. The present disclosure provides compounds, pharmaceutically acc... |
|
|
Invention
|
Pyruvate kinase r (pkr) activating compositions.
The present disclosure provides crystalline sol... |
|
2022
|
Invention
|
Treating patients harboring an isocitrate dehydrogenase-1 (idh-1) mutation.
Methods of treating ... |
|
|
Invention
|
Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors. The disclosure r... |
|
|
Invention
|
Inhibiting ubiquitin-specific protease 1 (usp1).
The present disclosure provides compounds for i... |
|
|
Invention
|
Inhibiting ubiquitin-specific protease 1 (usp1). The present disclosure provides compounds for in... |
|
|
Invention
|
Inhibiting mutant isocitrate dehydrogenase 1 (midh-1). Patients diagnosed with a cancer harboring... |
|
|
Invention
|
Inhibiting fatty acid synthase (fasn).
The present disclosure is directed to inhibitors of FASN.... |
|
|
Invention
|
Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors. The present disclosure is direc... |
|
|
Invention
|
Inhibiting creb binding protein (cbp).
The present disclosure is directed to inhibitors of the C... |
|
2021
|
Invention
|
Inhibiting ubiquitin specific peptidase 30.
The present disclosure relates to chemical entities ... |
|
|
Invention
|
Purinones as ubiquitin-specific protease 1 inhibitors. The application relates to inhibitors of U... |
|
|
Invention
|
Inhibiting cyclic amp-responsive element-binding protein (creb) binding protein (cbp). The presen... |
|
|
Invention
|
Bromodomain inhibitors for androgen receptor-driven cancers. Methods for treating certain androge... |
|
|
Invention
|
Tetrahydroquinoline compositions as bet bromodomain inhibitors.
The present invention relates to... |
|
|
Invention
|
Activating pyruvate kinase r and mutants thereof.
The disclosure provides chemical compounds use... |
|
|
Invention
|
Novel compounds and compositions for inhibition of fasn.
The present invention relates to compou... |
|
2020
|
Invention
|
Treating patients harboring an isocitrate dehydrogenase 1 (idh-1) mutation. Methods of treating p... |
|
|
Invention
|
Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors. The inve... |
|
|
Invention
|
Inhibiting mutant isocitrate dehydrogenase 1 (midh1). This disclosure relates to compositions and... |
|
|
Invention
|
Compositions for activating pyruvate kinase. Compositions for the activation of PKR are provided,... |
|
|
Invention
|
Activating pyruvate kinase r.
The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-y... |
|
|
Invention
|
Pyruvate kinase r (pkr) activating compositions. The present disclosure provides crystalline soli... |
|
|
Invention
|
Activating pyruvate kinase r. The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl... |
|
|
Invention
|
Inhibiting ubiquitin specific peptidase 9x. This disclosure provides methods of treating cancer w... |
|
|
Invention
|
Inhibiting fatty acid synthase (fasn). The present disclosure is directed to inhibitors of FASN. ... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the trea... |
|
|
Invention
|
Benzopiperazine compositions as bet bromodomain inhibitors. The present invention relates to inhi... |
|
|
Invention
|
Inhibiting cyclic amp-responsive element-binding protein (creb).
The present disclosure is direc... |
|
2019
|
Invention
|
Compositions for inhibiting ubiquitin specific protease 1.
This disclosure relates to modulating... |
|
|
Invention
|
Inhibiting ubiquitin specific peptidase 9x.
FLT3-ITD and FLT3-TKD are the most frequent mutation... |
|
|
Invention
|
Inhibiting ubiquitin specific peptidase 9x.
The disclosure provides novel chemical compounds use... |
|
|
Invention
|
Inhibiting ubiquitin specific peptidase 9x.
This disclosure provides methods of treating cancer ... |
|
|
Invention
|
Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1... |
|
|
Invention
|
Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors. The present disclo... |
|
|
Invention
|
Inhibiting mutant idh-1.
Methods of treating patients diagnosed with cancer harboring an IDH-1 m... |
|
2018
|
Invention
|
Treatment of glioblastoma with fasn inhibitors.
The present disclosure relates to methods of tre... |
|
|
P/S
|
research and development of pharmaceuticals for others; research and development of pharmaceutica... |
|
|
P/S
|
chemical compounds for use in bio-pharmaceutical research Pharmaceutical preparations for the tre... |
